Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis products reach nearly 1 billion people globally and we are finding innovative ways to expand access to our latest treatments. About 125,000 people of more than 140 nationalities work at Novartis around the world.
Business & Industry
- Pfizer and BioNTech achieve first authorization in the world for a vaccine to combat COVID-19
- Moderna announces primary efficacy analysis in Phase 3 COVE study for its COVID-19 vaccine candidate and filing today with U.S. FDA for Emergency Use Authorization
- Lilly's neutralizing antibody bamlanivimab (LY-CoV555) receives interim authorization from Health Canada as a treatment for COVID-19
- AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19
- Pfizer and BioNTech to submit Emergency Use Authorization request today to the U.S. FDA for COVID-19 vaccine
Research & Development
- Study finds metformin reduced COVID-19 death risks in women
- KU Leuven vaccine candidate protects against COVID-19 and yellow fever
- UK medicines regulator gives approval for first UK COVID-19 vaccine
- Predict cellular drug targets against COVID-19
- Doctors use existing treatment earlier to save the lives of COVID-19 patients
- European Commission approves contract with Moderna to ensure access to a potential vaccine
- New therapy for flu may help in fight against COVID-19
Conferences & Events
- CPhI Worldwide to return in 2021
- Reuters Events' Cell & Gene Therapy USA
- Total health: Build a better healthcare system
- Don't fall for the 'next best action' trap
- Locking down shape-shifting spike protein aids development of COVID-19 vaccine
- COVID-19 vaccine innovation could dramatically speed up worldwide production
- Wearable Injectors and Connected Devices Conference 2020
Regulatory Affairs
- EMA receives application for conditional marketing authorisation of COVID-19 mRNA vaccine BNT162b2
- EMA receives application for conditional marketing authorisation of Moderna COVID-19 vaccine
- FDA authorizes monoclonal antibodies for treatment of COVID-19
- FDA approves first treatment for COVID-19
- EMA endorses use of dexamethasone in COVID-19 patients on oxygen or mechanical ventilation